What this is
- This study investigates the effects of semaglutide, a GLP-1 receptor agonist, on metabolic and liver parameters in patients with type 2 diabetes mellitus (T2DM) and metabolic-associated fatty liver disease ().
- Using a multi-omics approach, the research analyzes serum proteomic and metabolomic profiles before and after 12 weeks of treatment.
- Significant improvements in metabolic markers and liver function were observed, along with changes in specific metabolites and proteins.
Essence
- Semaglutide treatment in T2DM- patients significantly improved metabolic and liver parameters, revealing distinct proteomic and metabolomic changes. This study provides insights into the mechanisms behind semaglutide's hepatic benefits.
Key takeaways
- Semaglutide treatment resulted in significant reductions in HbA1c, BMI, HOMA-IR, liver stiffness, ALT, AST, γ-GGT, TC, TG, and LDL-C levels, all with P-values < 0.01. HDL-C levels increased significantly (P-value < 0.05).
- A total of 203 differential metabolites and 61 proteins were identified post-treatment, indicating semaglutide's role in modulating fatty acid metabolism and inflammatory pathways.
- The study underscores the potential of semaglutide as a therapeutic agent for through its multi-omics effects on metabolic and inflammatory processes.
Caveats
- The study lacks direct functional validation of identified pathways and biomarkers, limiting the confirmation of mechanistic insights. Future research should involve larger cohorts and additional validation studies.
Definitions
- MAFLD: Metabolic-associated fatty liver disease, characterized by excessive lipid deposition in the liver linked to metabolic syndrome.
- GLP-1 receptor agonists: A class of drugs that enhance glucose metabolism and suppress appetite, showing potential benefits for liver health.
AI simplified
Introduction
Metabolic-associated fatty liver disease (MAFLD), the hepatic manifestation of the metabolic syndrome, has become the leading cause of chronic liver disease worldwide, with a prevalence of up to 20%, and is strongly associated with type 2 diabetes mellitus (T2DM), obesity and insulin resistance (1 –3).The hallmarks of MAFLD encompass excessive lipid deposition in hepatocytes, mitochondrial dysfunction, and a persistent inflammatory response. These features can ultimately lead to the development of non-alcoholic steatohepatitis (NASH), liver fibrosis, and even cirrhosis (4 –6). These features can ultimately lead to the development of non-alcoholic steatohepatitis (NASH), liver fibrosis, and even cirrhosis.
The pathogenesis of MAFLD is characterised by multiple metabolic imbalances, including enhanced de novo synthesis of intrahepatic lipids, impaired fatty acid β-oxidation, and aberrant activation of proinflammatory factors (e.g., IL-6, TGF-β1) (7, 8). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a novel class of glucagon-like peptide-1 drugs. These agents have been shown to enhance glucose and lipid metabolism by modulating insulin secretion and the appetite centre. Moreover, they have been observed to exert a direct effect on the liver, reducing hepatic steatosis through the inhibition of endoplasmic reticulum stress, the promotion of autophagy, and the restoration of mitochondrial function (9, 10). Of note, the therapeutic benefits of GLP-1 RAs extend beyond glycemic control and weight reduction. Emerging evidence suggests that these agents may exert protective effects across multiple organ systems. For instance, recent studies have indicated that GLP-1 RAs are associated with a lower risk of osteoarthritis and improved joint health, potentially through modulating inflammation and cartilage degradation (11). Furthermore, their anti-inflammatory and immunomodulatory properties may also play a role in reducing the risk or improving outcomes of bone and joint infections (12). These pleiotropic effects underscore the systemic impact of GLP-1 RAs and provide a compelling rationale for investigating their broader protective mechanisms, particularly in the context of multi-system metabolic disorders like MAFLD-T2DM. Of particular note is the long-acting GLP-1 RA semaglutide, which has garnered attention for its substantial weight reduction and cardioprotective properties. However, the precise molecular mechanisms through which it enhances liver outcomes in MAFLD remain to be fully elucidated.
At present, mechanistic studies of type 2 diabetes mellitus (T2DM) in combination with metabolic associated fatty liver disease (MAFLD) are largely confined to single-omics analyses (e.g. metabolome or proteome). This approach is inadequate for the comprehensive revelation of systemic molecular alterations in response to drug intervention (13). Metabolomics has been demonstrated to dynamically reflect the end-phenotypes of genes, proteins and environmental factors acting in combination (14), while proteomics has been shown to resolve the functional regulation of key effector molecules (15). Conducting an integrated analysis of the two can facilitate more precise localisation of disease-related pathways and therapeutic targets. However, there is still a paucity of systematic studies on the effect of semaglutide on the serum multi-omics characteristics of T2DM-MAFLD patients.
The present study utilised 4D-DIA proteomics and LC-MS metabolomics technology to longitudinally analyse the serum molecular characteristics of T2DM patients with MAFLD before and after semaglutide treatment. The objectives of this study are as follows: (1) to reveal the potential biomarkers of semaglutide in improving liver metabolism and inflammation, (2) to clarify the key pathways of its regulation of fatty acid metabolism, mitochondrial function and inflammatory response through multi-omics integration. The provision of a mechanistic basis for the hepatoprotective effect of GLP-1 RAs is of paramount importance, as is the promotion of precise treatment for MAFLD.
Methods
Research subjects
This study was conducted from June 2022 to June 2023 in the Department of Endocrinology at Shijiazhuang People's Hospital. The final sample comprised 75 patients with T2DM combined with MAFLD who met the specified criteria (PT group), and 100 healthy control subjects (HC group). The study protocol was approved by the Ethics Committee of Shijiazhuang People's Hospital (Ethics No. [2023]022), and all participants signed an informed consent form. The participant recruitment, grouping, and analysis workflow are summarized in Figure 1.
All patients with T2DM combined with MAFLD were treated with subcutaneous injections of semaglutide (Novo Nordisk) in addition to their basal glucose-lowering regimen at an initial dose of 0.25 mg/week, which was increased to 0.5 mg/week after one week. The treatment was continued for 12 weeks. A range of clinical indicators and serum samples were collected from patients before and after treatment.
Study flowchart outlining participant recruitment, intervention, and omics analysis. This flowchart outlines the recruitment, inclusion/exclusion criteria, treatment process, and sample selection for proteomic and metabolomic analyses of patients with T2DM-MAFLD from June 2022 to June 2023.
Inclusion of exclusion criteria
The admission criteria for this study are outlined below
(1) Age of the subject must be between 18 and 70 years. (2) A diagnosis of fatty liver disease must be made on the basis of an abdominal ultrasound. (3) The presence of liver fibrosis must be confirmed on the basis of early Nash (Metavir stage F0-F3). (4) The subject must meet the diagnostic criteria for T2DM as set out in the Chinese Type 2 Diabetes Prevention and Treatment Guidelines. (5) The subject's BMI must be between 25 and 35 kg/m². (6) The subject's HbA1c must be between 7% and 10%.
Exclusion criteria
(1) Patients with diabetes and poor glycemic control (HbA1c > 10%) will be excluded from the study. (2) Patients with severe liver function impairment (ALT or AST ≥5 times the upper limit of normal) will be excluded from the study. (3) Patients with other forms of liver diseases (e.g. hepatitis B, hepatitis C, autoimmune hepatitis) will be excluded from the study. (4) Patients using hypoglycemic drugs that affect hepatic steatosis (e.g. Thiazolidinedione, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, etc.) in the past 3 months. (e) used drugs such as methotrexate, tamoxifen and glucocorticoid. (6) there were contraindications to semaglutide (such as acute and chronic pancreatitis, pancreatic cancer). (7) severe kidney failure. (8) acute stage of cardiovascular and cerebrovascular diseases.
Collection of clinical data and detection of biochemical indexes
General information collection
A standardised electronic medical record system was utilised to document patients' baseline information, encompassing age, gender, BMI, waist-to-hip ratio, and current medication history.
The BMI of each participant was calculated as weight (kg)/height² (m²). The electronic weighing scale (accuracy ±0.1 kg) and the wall-mounted height meter (accuracy ±0.5 cm) were utilised for this purpose.
Waist-hip ratio: Waist circumference (the horizontal circumference of the midpoint between the upper edge of the iliac crest and the lower edge of the twelfth rib) and hip circumference (the horizontal circumference of the most prominent point of the buttocks) were measured by using a soft ruler, and the ratio of waist circumference/hip circumference was calculated.
Automatic biochemical analysis and testing
A fully automated biochemical analyser (AU5800, Beckman Coulter, USA) was utilised to ascertain serum biochemical indices, encompassing the following:
Liver function indices: alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyltransferase (GGT).
Furthermore, metabolic indicators such as fasting glucose (FPG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were also analysed.
Quality control: Instrument calibration and quality control products (Level 1 & 2, Roche Diagnostics) were performed daily, with an intra-batch coefficient of variation (CV) of less than 5%.
Fasting insulin measurement and HOMA-IR calculation
ASSAY: Serum FINS concentration was quantified by electrochemiluminescence (Cobas e601, Roche Diagnostics, Switzerland) with a sensitivity of 0.2 μIU/mL and a linear range of 1-300 μIU/mL.
HOMA-IR calculation: the steady-state model was evaluated with the formula:
HOMA-IR=FPG (mg/dL)×FINS (μIU/mL)/22.5.
FPG units were converted to mg/dL (1 mmol/L = 18 mg/dL).
Glycated hemoglobin (HbA1c) test
HbA1c was determined by high performance liquid chromatography (HPLC, D-10™, Burroughs, USA) with a detection range of 4.0-18.0% and a batch-to-batch CV of <2%.
ELISA
Cytokine IL-6 (EK1153) was purchased from Hangzhou Lianke Biotechnology Co., Ltd. The absorbance was measured using a full-wavelength enzyme-labeler (Multiskan SkyHigh, Thermo Fisher Scientific, Waltham, MA, USA).
Abdominal ultrasound evaluation of fatty liver disease
The radiologist maintained the confidentiality of other clinical information regarding the participants. Fatty liver was qualitatively evaluated based on the echogenicity of the hepatic parenchyma relative to the right renal cortex. The classification was as follows:
Normal: Homogeneous hepatic echogenicity with no posterior attenuation.
Mild Fatty Liver: Mildly increased hepatic echogenicity compared to the renal cortex, with minimal or no posterior attenuation.
Moderate to Severe Fatty Liver: Markedly increased hepatic echogenicity accompanied by significant posterior attenuation and blurred vascular texture.
Liver stiffness measurement
LSM was performed in the supine position using shear wave elastography (Mindray, Shenzhen, China) through the right intercostal space. Five measurements of liver stiffness were obtained. Liver fibrosis was staged according to the Metavir classification:
Follow-up
At the end of the 12-week semaglutide treatment, a total of 69 patients completed the study, while 6 patients withdrew due to drug side effects or personal reasons. The aforementioned indicators were re-measured using the same methods as before.
Subsequently, 12 serum samples were randomly selected from the 69 MAFLD patients who completed the treatment. These samples were designated as the after-treatment (AT) group, representing the serum collected after 12 weeks of treatment. Additionally, 12 serum samples were selected from the 100 patients in the HC group. In total, 36 samples were subjected to serum proteomics analysis.
For metabolomics analysis, 15 additional samples were added to each of the PT and AT groups, while the HC group remained unchanged. This resulted in a total of 66 samples being analyzed for serum metabolomics.
Serum metabolomic assay
Sample preparation and extraction
Samples stored at -80°C were thawed on ice and mixed with the extraction solution containing the internal standard. After vortexing and centrifugation, the supernatant was collected, briefly frozen and then centrifuged a second time. The final supernatant was used for LC-MS analysis, and the volume was adjusted to 180 μL for plasma samples and 120 μL for atrial fluid samples.Metabolite extraction and LC-MS analysis were performed with reference to the International Guidelines for Standardization in Metabolomics (16), using a Waters ACQUITY UPLC BEH C18 column (1.7 μm, 2.1 × 100 mm) with a mobile phase A of 0.1% formic acid aqueous solution, mobile phase B was 0.1% formic acid acetonitrile solution, and the gradient elution program was as follows: 0–2 min 5% B, 2–10 min 5-95% B, 10–12 min 95% B. The separation was performed on a Waters ACQUITY UPLC BEH C18 column (1.7 μm, 2.1×100 mm).
Detection conditions
A liquid chromatography-mass spectrometry (LC-MS) system equipped with a Waters ACQUITY UPLC BEH C18 column was used for the analysis of the samples, with the temperature of the column maintained at 40°C and the flow rate of 0.4 mL/min. The gradient solvent system was started with a water-acetonitrile ratio of 95:5 and gradually varied to different ratios over a period of 10 min. an AB Sciex TripleTOF 6600 mass spectrometer was operated in full MS-scan mode (full MS-scan mode), while data were acquired in positive and negative ionization modes with specific ion source parameters and scanning parameters set, including mass range, integration time, and collision energy. Information-dependent acquisition (IDA) of data was performed using Analyst TF 1.7.1 software.
Metabolic characterization
Raw mass spectrometry data were converted to mzXML format using ProteoWizard software and peak detection and alignment based on mass-to-charge ratio (m/z) and retention time was performed by XCMS software. Metabolites were quantified and calibrated by SVR method. Metabolite identification was accomplished by a four-step method involving internal standard libraries, public databases, and software tools such as MetDNA and CFM-ID. The identification priority was in the following order: standard, MS/MS and MetDNA, and the similarity score threshold for MS/MS spectra matching was set at 0.5.
Serum proteomic assays
Preparation of protein and peptide samples
Samples were thawed on ice, mixed with PBS and PMSF, and subsequently shaken at room temperature to determine total protein concentration using the BCA method. Aliquots of protein samples were subjected to a trypsin digestion process including reduction, alkylation, and precipitation, followed by resuspension and overnight digestion at 37°C. Digested peptides were desalted, dried, and redissolved in formic acid for further analysis.
LC-MS/MS-based proteomics analysis
Liquid chromatography analysis was performed on a nanoElute UHPLC system with a reversed-phase C18 column at 50°C for peptide separation at a flow rate of 0.3 μL/min and a separation time of 60 min. Mobile phase B increased linearly from 2% to 80% within the first 55 min. The liquid chromatography was coupled to a timsTOF Pro2 mass spectrometer running in PASEF mode to acquire MS and MS/MS spectra in the range of 100 to 1700 m/z with a capillary voltage of 1400 V. In diaPASEF mode, the software defined 64 quadrupole isolation windows based on the TIMS scan time and adjusted the collision energies and isolation widths according to the m/z values. Mass spectrometry data acquisition was performed in diaPASEF mode, with collision energies set to 20–50 eV and isolation window widths to 2 Th. Protein identification was performed via the SwissProt database (Release 2023_01), and a reverse database strategy was used to control the false-positive rate (17).
Protein database search
MS raw data were analyzed in a library-free manner using DIA-NN (v1.8.1) software. Spectral libraries were created using the human (Homo sapiens) SwissProt database and deep learning algorithms for neural networks. The MBR option was used to create a spectral library from the DIA data and the data was re-analyzed using this spectral library. The false discovery rate (FDR) of the search results was adjusted to an average of less than 1% for proteins and precursor ionized water, and the remaining identifications were used for subsequent quantitative analysis.
Statistical analysis
This study used SPSS 26.0 statistical analysis software for data analysis. The quantitative data did not obey normal distribution by normality test, and the non-normally distributed variables were expressed as Interquartile range (IQR). Qualitative variables were expressed as percentages. The nonparametric Wilcoxon rank sum test was applied to the nonnormally distributed data, and P<0.05 was considered statistically significant. Differences between metabolic and protein group data were analyzed using the Benjamini-Hochberg method corrected for false discovery rate (FDR < 0.05) (18).
Result
Clinical and biochemical characteristics
Following a 12-week period of semaglutide treatment, patients diagnosed with T2DM-MAFLD demonstrated substantial enhancements in metabolic and hepatic parameters. Compared to the PT group, the AT group demonstrated significant reductions in HbA1c, BMI, HOMA-IR, liver stiffness (LSM), ALT, AST, γ-GGT, TC, TG, LDL-C, and IL-6 levels (all P-values < 0.01), while HDL-C levels exhibited a significant increase (P-value < 0.05). No significant changes were observed in uric acid (UA) levels (Tables 1, 2). Furthermore, baseline levels of all metabolic and inflammatory markers in the healthy control group (HC group) were found to be significantly lower than those in the PT group (P-values < 0.05) (Table 1, Supplementary Table S1).
| Basic characteristics | ZC-group | ZLQ-group | Z-score | -valueP |
|---|---|---|---|---|
| Sample size (n) | 100 | 69 | ||
| Age (year) | 40.50 (35.00, 45.00) | 46.00 (36.00, 54.00) | 2.938 | 2.938 |
| Gender (male,%) | 38 (38.0) | 49 (71.0) | 17.816 | <0.001 |
| BMI (kg/m)2 | 21.09 (20.05, 22.78) | 28.72 (27.50, 32.07) | -10.768 | <0.001 |
| Waist-to-Hip Ratio | 0.78 (0.72, 0.86) | 0.97 (0.95, 0.99) | -10.939 | <0.001 |
| FIB-4 | 0.83 (0.61, 1.18) | 1.11 (0.84, 1.63) | -3.173 | 0.002 |
| ALT (U/L) | 23.30 (17.00, 31.00) | 45.00 (40.50, 52.50) | -10.608 | <0.001 |
| r-GGT (U/L) | 22.50 (16.00, 32.00) | 37.00 (28.00, 51.50) | -6.52 | <0.001 |
| AST (U/L) | 21.50 (17.00, 27.75) | 42.00 (39.00, 45.00) | -10.275 | <0.001 |
| FPG (mmol/L) | 5.09 (4.70, 5.45) | 9.60 (7.50, 11.65) | -10.865 | <0.001 |
| UA (μmol/L) | 281.00 (191.00, 321.00) | 378.00 (308.00, 440.00) | 7.336 | <0.001 |
| TC (mmol/L) | 4.18 (3.54, 4.77) | 5.94 (5.50, 6.87) | -10.755 | <0.001 |
| TG (mmol/L) | 1.12(0.88, 1.45) | 2.43 (1.94, 3.00) | -10.293 | <0.001 |
| HDL-C (mmol/L) | 1.41(1.22, 1.52) | 1.06 (0.93, 1.17) | -7.772 | <0.001 |
| LDL-C (mmol/L) | 2.38(1.98, 2.87) | 3.91 (3.73, 4.25) | -10.749 | <0.001 |
| Bile Acids (μmol/L) | 5.20 (3.10, 6.88) | 2.80 (1.90, 3.90) | 5.479 | <0.001 |
| IL-6 (pg/ml) | 4.14 (3.97, 4.41) | 5.21 (5.00, 5.66) | -10.818 | <0.001 |
| Basic characteristics | ZC-group | ZLQ-group | Z-score | -valueP |
|---|---|---|---|---|
| Sample size(n) | 69 | 69 | ||
| BMI (kg/m)2 | 28.72 (27.50, 32.07) | 23.65 (22.33, 24.45) | -7.22 | <0.001 |
| Waist-to-Hip Ratio | 0.97 (0.95, 0.99) | 0.85 (0.80, 0.88) | -7.224 | <0.001 |
| FIB-4 | 1.11 (0.84, 1.63) | 0.79 (0.57, 1.06) | -5.307 | <0.001 |
| ALT (U/L) | 45.00(40.50,52.50) | 32.00 (23.50, 35.00) | -7.055 | <0.001 |
| r-GGT (U/L) | 37.00 (28.00, 51.50) | 30.00 (22.50, 40.00) | -4.495 | <0.001 |
| AST (U/L) | 42.00 (39.00, 45.00) | 25.00 (21.00, 29.50) | -7.127 | <0.001 |
| FPG (mmol/L) | 9.60 (7.50, 11.65) | 5.70 (5.00, 6.20) | -6.878 | <0.001 |
| UA (μmol/L) | 378.00 (308.00, 440.00) | 367.00 (309.00, 435.00) | 0.914 | 0.361 |
| TC (mmol/L) | 5.94 (5.50, 6.87) | 4.48 (3.62, 4.92) | -7.059 | <0.001 |
| TG (mmol/L) | 2.43 (1.94, 3.00) | 1.37 (1.02, 1.70) | -6.593 | <0.001 |
| HDL-C (mmol/L) | 1.06 (0.93, 1.17) | 1.42 (1.20, 1.52) | -5.563 | <0.001 |
| LDL-C (mmol/L) | 3.91 (3.73, 4.25) | 2.87 (2.18, 3.10) | -6.994 | <0.001 |
| Bile Acids (μmol/L) | 2.80 (1.90, 3.90) | 2.80 (2.00, 3.85) | 7.221 | <0.001 |
| IL-6 (pg/ml) | 5.21 (5.00, 5.66) | 4.17 (3.98, 4.70) | -7.056 | <0.001 |
| HbA1c(%) | 8.30 (7.15, 9.85) | 5.80 (5.15, 6.10) | -6.966 | <0.001 |
| FINS(μIU/ml) | 19.30 (15.10, 25.90) | 7.00 (2.00, 12.95) | -5.977 | <0.001 |
| HOMA-IR | 9.00 (6.25, 11.80) | 5.10 (2.90, 7.95) | -6.987 | <0.001 |
| LSM (kPa) | 5.78(5.51,6.10) | 1.61 (0.91, 2.00) | -7.171 | <0.001 |
Serum metabolomics analysis
Metabolomics analysis revealed significant differences in metabolic profiles among the healthy control group (HC group), baseline MAFLD group (PT group), and post-treatment group (AT group) (Figure 2A). Principal component analysis (PCA) demonstrated clear separation between the HC, PT, and AT groups (Figure 2B). KEGG pathway analysis indicated that semaglutide modulates pathways related to unsaturated fatty acid biosynthesis, PPAR signaling, and NAFLD (P-value < 0.05) (Figure 2C). The R²Y and Q² values of the OPLS-DA model were 0.983 and 0.697, respectively, indicating strong discrimination of metabolic features between groups (Figures 2D-F).
Metabolomic profiling and pathway analysis.Circular chart of metabolite category composition (each color represents a metabolite category, and the area of the color block indicates the proportion of that category).Principal Component Analysis (PCA) score plot demonstrating distinct clustering of HC, PT, and AT groups.KEGG pathway analysis showing enriched pathways related to fatty acid metabolism and NAFLD (P < 0.05).Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) model validation for AT vs. HC, AT vs. PT, and PT vs. HCgroups.Volcano plot of differentially expressed metabolites between PT and HC groups.Volcano plot of differentially expressed metabolites between AT and PT groups. (A) (B) (C) (D-F) (D) (E) (F) (G) (H)
Identification and screening of differential metabolites
Differential metabolite analysis identified 219 differentially expressed metabolites (131 of which were found to be expressed at a higher level and 88 at a lower level) between the PT and HC groups (Figure 2G), and 203 metabolites (121 of which were found to be expressed at a higher level and 82 at a lower level) between the AT and PT groups (Figure 2H). The volcano plot visually summarizes these changes and highlights the top 10 most significantly up- and down-regulated metabolites (Figures 2G, H). Compared to the HC group, significantly upregulated metabolites in the PT group included glycerophospholipids (e.g., LPC 0:0/19:0, LPA 0:0/16:0) and pro-inflammatory free fatty acids (e.g., arachidonic acid, prostaglandin B1) (Table 3). Following semaglutide treatment (AT group), levels of long-chain fatty acids (e.g., 12,13-EpOME, 9(S)-HODE) were found to be significantly downregulated, while levels of carnitine derivatives (e.g., Carnitine C10:1-OH) were significantly upregulated (Table 3). The screening criteria for differential metabolites were set as follows: VIP ≥1.0 and FC ≥1.5 or ≤0.66(Supplementary Table S2).
| Names | Categories | ZC | ZLQ | ZLH | VIP | P |
|---|---|---|---|---|---|---|
| 12,13-EpOME | FA | 32576.99 | 80191.19 | 27737.97 | 1.48 | 0.01 |
| 4-Hydroxy-2-Oxoglutaric Acid | Organic acid and its derivatives | 170153 | 228378.7 | 166567.34 | 1.89 | <0.001 |
| 5,6-Dimethylbenzimidazole | Heterocyclic compounds | 250420.92 | 269862.57 | 181653.51 | 1.05 | <0.001 |
| 9(S),12(S),13(S)-TriHOME | FA | 35349.17 | 61130.86 | 31957.37 | 2.03 | <0.001 |
| 9(S)-HODE | FA | 71918.91 | 153250.1 | 62417.82 | 2.18 | <0.001 |
| DL-3,4-Dihydroxyphenyl glycol | Benzene and substituted derivatives | 44482.66 | 86868.98 | 47796.93 | 2.26 | <0.001 |
| Dulcitol | Carbohydrates and its metabolites | 21044.78 | 33595.78 | 20015.07 | 1.42 | 0.005 |
| Glycodeoxycholic acid | Bile acids | 2806590.77 | 5186714.38 | 1890707.41 | 1.05 | 0.004 |
| L-Homoarginine | Amino acid and its metabolites | 426630.75 | 564012.96 | 417440.44 | 1.02 | 0.03 |
| Leu-Ala-Val | Amino acid and its metabolites | 29109.02 | 54477.71 | 35858.9 | 1.94 | 0.002 |
| Glycodeoxycholic acid | Amino acid and its metabolites | 44537439.88 | 54702050.79 | 47012997.48 | 1.59 | 0.006 |
| N-Acetyl-L-Tyrosine | Amino acid and its metabolites | 167209.15 | 205909.58 | 178245.62 | 1.38 | 0.004 |
| O-Acetyl-L-homoserine | Amino acid and its metabolites | 186699.08 | 219504.06 | 181660 | 1.47 | 0.002 |
| Spermidine | Alcohol and amines | 183949.2 | 229780.98 | 190279.9 | 1.38 | 0.004 |
| Trans-4-Hydroxy-L-Proline | Amino acid and Its metabolites | 97458.74 | 115603.71 | 91504.37 | 1.3 | 0.004 |
| Traumatic acid | Organic acid and its derivatives | 275052.52 | 586723.03 | 301985.39 | 1.81 | 0.02 |
| Tyr-Ala | Amino acid and its metabolites | 76804.8 | 100094.34 | 65605.66 | 1.11 | 0.001 |
| Val-Ala | Amino acid and its metabolites | 3341069.35 | 6461831.3 | 3326888.57 | 2.14 | <0.001 |
| estrone 3-sulfate | Hormones and hormone-relatedcompounds | 178094.55 | 1045691.35 | 260407.66 | 1.54 | 0.001 |
| 2-Amino-3-phosphonopropionic acid | Organic acid and its derivatives | 634961.5 | 478289.74 | 607289.68 | 1.23 | 0.02 |
| 2-Aminophenol | Benzene and substituted derivatives | 409140.13 | 285643.66 | 329695.44 | 1.7 | 0.005 |
| 2-Hydroxyethanesulfonate | Organic acid and its derivatives | 555278.22 | 414614 | 516418.8 | 1.69 | 0.001 |
| 4-Hydroxy-3-methoxybenzaldehyde | Benzene and substituted derivatives | 840670.99 | 564811.11 | 582685.63 | 1.35 | 0.0007 |
| 4-Hydroxybenzoic Acid | Benzene and substituted derivatives | 1239577.51 | 551946.26 | 560838.35 | 1.8 | <0.001 |
| 4-Hydroxyretinoic Acid | CoEnzyme and vitamins | 211542.89 | 118741.96 | 147281.11 | 1.81 | 0.003 |
| Arg-Phe-Val-Asp | Amino acid and metabolites | 19094.23 | 15177.99 | 15314.9 | 1.25 | 0.003 |
| Corticosterone | Hormones and hormone-related compounds | 28645.62 | 13417.03 | 16981.5 | 1.32 | 0.006 |
| FFA (22:1) | FA | 12941458.05 | 4122480.71 | 4477635.29 | 2.32 | <0.001 |
| Gly-Phe | Amino acid and its metabolites | 2015452.57 | 1241134.23 | 1946123.43 | 1.15 | 0.01 |
| Guanidinoethyl Sulfonate | Organic acid and its derivatives | 138775.35 | 115191.08 | 115748.54 | 1.63 | <0.001 |
| Hyp-Thr | Amino acid and its metabolites | 414925.03 | 283973.8 | 291459.2 | 2.01 | <0.001 |
| Ile-Ala | Amino acid and its metabolites | 171623.79 | 86298.52 | 100496.58 | 1.67 | <0.001 |
| Ile-Leu | Amino acid and its metabolites | 486836.88 | 301940.82 | 370448.5 | 1.28 | 0.02 |
| Imidazoleacetic acid | Heterocyclic compounds | 129760.55 | 96956.3 | 125183.57 | 1.34 | 0.01 |
| LPC (O-20:3) | GP | 398934.09 | 225390.29 | 275163.15 | 2.24 | 0.01 |
| LPC (O-22:2) | GP | 1539101.65 | 978159.03 | 1177322.9 | 2.1 | <0.001 |
| LPG (18:0) | GP | 100174.38 | 79241.73 | 97459.17 | 1.4 | 0.008 |
| LPG (20:1) | GP | 6744.29 | 1376.15 | 1461.64 | 3.07 | <0.001 |
| Oxindole | Heterocyclic compounds | 1035187.15 | 547573.34 | 891405.68 | 1.69 | 0.008 |
| Phe-Gly | Amino acid and its metabolites | 1865292.16 | 1174481.24 | 1769224.08 | 1.04 | 0.02 |
| Piperidine acid | Organic acid and its derivatives | 35740774.03 | 21224954.91 | 23306468.11 | 1.75 | <0.001 |
| Trp-Glu | Amino acid and its metabolites | 48782.13 | 23819.83 | 43064.02 | 1.92 | <0.001 |
| Tyrosol | Benzene and substituted derivatives | 1444671.09 | 653398.08 | 685588.02 | 1.81 | <0.001 |
| Uracil | Nucleotide and its metabolites | 987514.82 | 701753.64 | 893174.36 | 1.8 | 0.0002 |
| Uric acid | Organic acid and its derivatives | 41671186.07 | 23307718.65 | 38273602.11 | 1.72 | 0.0004 |
Correlation between clinical indices and metabolites
Further analysis was conducted to examine the correlations between HOMA-IR, liver stiffness (LSM), and differential metabolites (Supplementary Figure S1). HOMA-IR exhibited positive correlations with metabolites such as 4-Hydroxy-2-Oxoglutaric Acid and 9(S),12(S),13(S)-TriHOME (r > 0, P < 0.05), and negative correlations with metabolites such as 2-Amino-3-phosphonopropionic acid and Gly-Phe (r < 0, P < 0.05) (Table 4). LSM showed positive correlations with 12,13-EpOME and traumatin, and a negative correlation with LPC(O-20:3) (Table 5). These findings suggest that semaglutide improves insulin resistance and hepatic fibrosis by modulating metabolite levels (Supplementary Table S3).
| Names | Clinical Indicators | r | P |
|---|---|---|---|
| 4-Hydroxy-2-Oxoglutaric Acid | HOMA-IR | 0.34 | 0.01 |
| 5,6-Dimethylbenzimidazole | HOMA-IR | 0.42 | 0.001 |
| 9(S),12(S),13(S)-TriHOME | HOMA-IR | 0.37 | 0.004 |
| DL-3,4-Dihydroxyphenyl glycol | HOMA-IR | 0.38 | 0.003 |
| Dulcitol | HOMA-IR | 0.32 | 0.01 |
| Leu-Ala-Val | HOMA-IR | 0.3 | 0.02 |
| N-Acetyl-L-Tyrosine | HOMA-IR | 0.28 | 0.03 |
| O-Acetyl-L-homoserine | HOMA-IR | 0.33 | 0.01 |
| Tyr-Ala | HOMA-IR | 0.32 | 0.01 |
| Val-Ala | HOMA-IR | 0.39 | 0.003 |
| 2-Amino-3-phosphonopropionic acid | HOMA-IR | -0.39 | 0.003 |
| 2-Hydroxyethanesulfonate | HOMA-IR | -0.38 | 0.004 |
| Gly-Phe | HOMA-IR | -0.41 | 0.002 |
| Imidazoleacetic acid | HOMA-IR | -0.33 | 0.01 |
| Phe-Gly | HOMA-IR | -0.37 | 0.005 |
| Trp-Glu | HOMA-IR | -0.27 | 0.04 |
| Uric acid | HOMA-IR | -0.5 | <0.001P |
| Names | Clinical Indicators | r | P |
|---|---|---|---|
| 12,13-EpOME | LSM | 0.37 | 0.006 |
| 4-Hydroxy-2-Oxoglutaric Acid | LSM | 0.29 | 0.03 |
| 5,6-Dimethylbenzimidazole | LSM | 0.3 | 0.02 |
| 9(S),12(S),13(S)-TriHOME | LSM | 0.45 | <0.001P |
| 9(S)-HODE | LSM | 0.57 | <0.001P |
| DL-3,4-Dihydroxyphenyl glycol | LSM | 0.48 | <0.001P |
| Dulcitol | LSM | 0.43 | 0.001 |
| Glycochenodeoxycholic Acid | LSM | 0.36 | 0.006 |
| Lysine | LSM | 0.38 | 0.005 |
| Spermidine | LSM | 0.34 | 0.01 |
| Trans-4-Hydroxy-L-Proline | LSM | 0.36 | 0.006 |
| Traumatic acid | LSM | 0.53 | <0.001P |
| Val-Ala | LSM | 0.5 | <0.001P |
| estrone 3-sulfate | LSM | 0.32 | 0.01 |
| 2-Amino-3-phosphonopropionic acid | LSM | -0.32 | 0.01 |
| 2-Hydroxyethanesulfonate | LSM | -0.34 | 0.01 |
| Corticosterone | LSM | -0.3 | 0.02 |
| FFA(22:1) | LSM | -0.31 | 0.02 |
| Imidazoleacetic acid | LSM | -0.28 | 0.03 |
| LPC(O-20:3) | LSM | -0.27 | 0.04 |
| LPC(O-22:2) | LSM | -0.33 | 0.01 |
| LPG(18:0) | LSM | -0.31 | 0.02 |
| Oxindole | LSM | -0.32 | 0.01 |
Serum proteomic analysis
Proteomic analysis identified 344 differentially expressed proteins (DEPs) between the PT and HC groups, of which 276 were up-regulated and 68 were down-regulated, as well as 61 DEPs between the AT and PT groups, of which 20 were up-regulated and 41 were down-regulated (Figures 3A, B; Supplementary Tables S4 and S5).
Protein domain and pathway enrichment analysis.Volcano plot of differentially expressed proteins between the PT group and the HC group.Volcano plot of differentially expressed proteins between the AT group and the PT group.Bar plot and bubble plot illustrating protein domain distributions between the PT and HC groups, with enrichment in kinases, peptidases, and phosphatases highlighted.Bubble plots depicting pathway enrichment for glycolysis/gluconeogenesisand mitochondrial β-oxidation.Protein domain distributions in the comparison between the AT and PT groups. (A) (B) (C) (D, E) (D) (E) (F)
Differential protein domain analysis
Analysis of the differential protein domains revealed that the prominent domains of the differential proteins between the PT and HC groups were mainly associated with protein kinases, peptidases and phosphatases (Figure 3C). These domains are significantly enriched in metabolic pathways such as glycolysis, gluconeogenesis, and Fatty acid metabolism(Figures 3D, E). In contrast, the differential proteins between the AT group and the PT group exhibited different domain distributions, with a higher proportion of domains associated with oxidoreductase and chaperones (Figure 3F). The detailed distribution of the displayed in Figure 4, indicating the distribution of differential proteins in different subcellular structures (Figure 4).
Subcellular localization of differential proteins.Subcellular distribution of proteins altered post-semaglutide treatment (AT vs. PT), predominantly localized in the cytoplasm (27.87%) and nucleus (26.23%).Localization of differential proteins between PT and HC groups, illustrating compartment-specific metabolic and regulatory functions. (A) (B)
GO analysis of differential proteins
GO analysis of the differential proteins identified several significantly enriched biological processes, including metabolic processes, cellular component organization, and response to stimuli (Figure 5A). These findings suggest that the differential proteins identified in this study are associated with a wide range of biological functions and pathways, further revealing the mechanism of the effect of semaglutide on T2DM-MAFLD. The results of Go functional classification analysis of differential proteins in PT and HC groups are displayed in Figure 5B, revealing the enrichment of differential proteins in different biological processes.
Functional annotation of differential proteins.Gene Ontology (GO) analysis of biological processes modulated by semaglutide, including metabolic regulation, cellular organization, and inflammatory response.GO classification of proteins differentially expressed in PT vs. HC groups, enriched in lipid metabolism and stress response pathways. (A) (B)
Proteome-metabolome integration analysis
Combining proteomic and metabolomic data, it was found that semaglutide affects metabolic pathways by regulating key enzymes and transporters (Figure 6). For instance, the upregulation of ITIH3 and INHBB was associated with decreased levels of pro-inflammatory metabolites such as LPC 18:1/0:0. Conversely, the downregulation of ACO1, ACAT1, and STAT1 has been linked to a decrease in lipid synthesis and inflammation. The heatmap in Figure 5 presents a visual representation of the correlation between differential protein and metabolite expression, with the horizontal axis representing differential proteins, the vertical axis representing differential metabolites, and + representing a correlation with an absolute value greater than 0.6.
Integrated proteomic-metabolomic network analysis. Heatmap depicting correlations between differentially expressed proteins (horizontal axis) and metabolites (vertical axis) (|r| > 0.6).
Discussion
In recent years, therapeutic strategies for metabolic dysfunction-associated fatty liver disease (MAFLD) have evolved from single-target interventions to multi-target synergistic regulation, addressing its complex metabolic-inflammatory-fibrotic pathological network. This study demonstrates that obese T2DM patients with MAFLD exhibit significant glucolipid metabolic disorders, impaired islet function, hepatic dysfunction, and elevated inflammatory markers, including BMI, FPG, FINS, HOMA-IR, HbA1c, TC, TG, LDL-C, ALT, AST, and IL-6 levels, all significantly higher than healthy controls. Semaglutide intervention substantially improved these parameters. Multivariate analysis models further revealed distinct separations in metabolomic and proteomic profiles among healthy controls, baseline MAFLD patients, and post-treatment groups, indicating that semaglutide-induced systemic molecular remodeling constitutes a key mechanism for hepatic outcome improvement.
Metabolomic profiling identified significant upregulation of glycerophospholipids (e.g., LPC 0:0/19:0, LPA 0:0/16:0) and pro-inflammatory free fatty acids (FFAs, including arachidonic acid and prostaglandin B1) in MAFLD patients. Glycerophospholipids contribute to MAFLD progression through oxidative stress activation and pro-inflammatory cytokine induction (e.g., IL-6, TNF-α) (19), while excessive FFAs suppress mitochondrial β-oxidation and induce hepatocyte lipotoxicity (20). Semaglutide treatment significantly reduced long-chain fatty acids (12,13-EpOME, 9(S)-HODE) while enhancing carnitine derivatives (Carnitine C10:1-OH). Carnitine facilitates mitochondrial fatty acid transport to enhance β-oxidation capacity and reduce lipotoxic intermediate accumulation (e.g., ceramides) (21), aligning with GLP-1 RAs' mechanism of AMPK-PPARα pathway activation for lipid synthesis/decomposition balance (9), suggesting semaglutide's "dual regulatory" effects on hepatic lipid metabolism.
Proteomic analysis revealed semaglutide-mediated downregulation of inflammatory mediators (STAT1, TGFB1I1) and apoptotic executor CASP3. STAT1, a core regulator of interferon signaling, drives MAFLD-to-NASH progression (22), while CASP3 promotes hepatocyte apoptosis and fibroinflammatory cascades under lipotoxic stress (23). The observed CASP3 reduction correlated with IL-6 attenuation and liver stiffness improvement, suggesting semaglutide interrupts the "metabolic-inflammatory-fibrotic" vicious cycle. Notably, semaglutide reversed MAFLD-associated SRSF1 upregulation, a splicing factor exacerbating FFA-induced hepatocyte inflammation (24).
Semaglutide elevated branched-chain amino acids (BCAAs: valine, leucine, isoleucine), potentially inhibiting lipogenic genes (e.g., SREBP-1c) via AMPK activation while enhancing β-oxidation (25). Concurrent increases in serine and taurine may mitigate oxidative stress through glutathione system restoration and SOD activity enhancement (26, 27). Intriguingly, semaglutide upregulated ITIH3 expression, a mitochondrial respiration enhancer inversely associated with MAFLD severity (28), and downregulated ACAT1, suggesting improved metabolic homeostasis through ketogenesis-lipolysis balance modulation (29).
Integrated multi-omics analysis demonstrated semaglutide's predominant effects on fatty acid metabolism and NAFLD-related pathways. ITIH3 upregulation positively correlated with anti-inflammatory metabolites (Bisindolylmaleimide I) and antioxidant polysaccharides (galacturonic acid), indicating potential downstream hepatoprotective mechanisms. INHBB upregulation, negatively associated with Gly-Lys levels, may ameliorate metabolic dysregulation through anti-inflammatory cytokine modulation.
This study has several limitations. First, although we identified significant alterations in pathways such as fatty acid β-oxidation and PPAR signaling, we lacked direct functional validation through experiments such as mitochondrial respiration assays, gene expression analysis of key regulators (e.g., PPARα target genes), or isotopic tracing of fatty acid oxidation. Second, as a single-center study with limited omics sample size, future validation in larger cohorts is warranted to confirm ITIH3 and ACAT1 as biomarkers. Mechanistic studies using ITIH3 knockout models and investigations into semaglutide-SGLT2 inhibitor combination therapies hold significant clinical implications.
Conclusion
In summary, the present study analyzed the molecular network of semaglutide to improve the hepatic outcome of T2DM-MAFLD at a multi-omics level, and revealed the innovative mechanism of its therapeutic effects through the metabolic-inflammatory-mitochondrial axis. These findings not only deepen the understanding of the multi-organ protective effects of GLP-1 RAs, but also provide a theoretical basis for the development of MAFLD therapeutic strategies based on multi-target modulation. Future studies could further explore the combination of semaglutide with other metabolic modulators (e.g., SGLT2 inhibitors) with the aim of achieving better clinical outcomes.